Another look at the implications of the DCCT study;Un autre regard sur les implications de l'étude DCCT

Annales d'Endocrinologie

Volumn 65, Issue 5, 2004, Pages 429-435

  Krzentowski, G ^a   Zhang, L ^b   Albert, A ^b   Lefebvre P J ^b  

^a Centre Hospitalier Universitaire de Charleroi   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Diabetic nephropathy; Diabetic retinopathy; Good metabolic control; Poor metabolic control

Indexed keywords

ALBUMIN; HEMOGLOBIN A1C;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; METABOLIC REGULATION; MICROALBUMINURIA; PROBABILITY; RISK FACTOR;

EID: 9344260299     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4266(04)95947-1     Document Type: Article

References (27)

1. American Diabetes Association. Clinical practice recommendations 2003. Diabetes Care 2003; 26 (suppl. 1): S1-S156.
2. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2002. Diabetes Care 2003; 26: 917-932.
3. Donaghue KC, Fairchild JM, Craig ME, et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care 2003; 26: 1224-1229.
4. European Diabetes Policy Group. A Desktop Guide to Type 1 (insulin-dependent) Diabetes Mellitus: Guidelines for Diabetes Care. Brussels, International Diabetes Federation European Region 1998.
5. Klein RL, Hunter SJ, Jenkins AJ, et al. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 2003; 26: 1439-1448.
6. Kullberg CE, Abrahamsson M, Arnqvist HJ, Finnström K, Ludvigsson J. For the Viss Study Group: Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with type 1 diabetes. Diabet Med 2002; 19: 924-931.
7. Malone JI, Morrison AD, Pavan PR, Cuthbertson DD. Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the Diabetes Control and Complications Trial. Diabetes Care 2001; 24: 522-526.
8. Orchard TJ, Forrest KY, Kuller LH, Becker DJ. How important are lipids and blood pressure for progression of complications in type 1 diabetes? International Diabetes Monitor 2002; 14: 7-9.
9. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 2285-2293.
10. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; 1: 168-188.
11. Porta M, Sjølie AK, Chaturvedi N, et al. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001; 44: 2203-2209.
12. Rogus JJ, Warram JH, Krolewski AS. Genetic studies of late diabetic complications: the overlooked importance of diabetes duration before complication onset. Diabetes 2002; 51: 1655-1662.
13. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002; 25: 859-864.
14. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146.
15. Steffes MW, Sibley S, Jackson M, Thomas W. β-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832-836.
16. The DCCT Research Group. Design and methodologic considerations for the feasibility phase. Diabetes 1986; 35: 530-545.
17. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual Beta-cell function: Observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987; 65: 30-36.
18. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
19. The Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995; 102: 647-661.
20. The DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298.
21. The DCCT Research Group. Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 1829-1839.
22. The DCCT Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389.
23. The DCCT Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569.
24. The DCCT Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-2303.
25. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-542.
26. Zhang L, Krzentowski G, Albert A, Lefèbvre PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2000; 24: 1275-1279.
27. Zhang L, Krzentowski G, Albert A, Lefèbvre PJ. Factors predictive of nephropathy in DCCT type 1 diabetic patients with good or poor metabolic control. Diabet Med 2003; 20: 580-285.